Guray Saydam, Ali Unal, Ibrahim Celalettin Haznedaroglu, Abdullah Hacihanifioglu, Ozgur Mehtap, Erdal Kurtoglu, Mesut Gocer, Mehmet Turgut, Engin Kelkitli, Memis Hilmi Atay, Nil Guler, Basak Unver Koluman, Mehmet Sonmez, Nergiz Erkut, Emin Kaya, Irfan Kuku, Mehmet Ali Erkurt, Gulsum Ozet, Funda Ceran, Fahri Sahin, Nur Soyer, Meliha Nalcaci, Mehmet Yilmaz, Sirac Bozkurt, Birkan Aver, Begum Ozdengulsun, Egemen Ozbilgili, Osman Ilhan
{"title":"Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia.","authors":"Guray Saydam, Ali Unal, Ibrahim Celalettin Haznedaroglu, Abdullah Hacihanifioglu, Ozgur Mehtap, Erdal Kurtoglu, Mesut Gocer, Mehmet Turgut, Engin Kelkitli, Memis Hilmi Atay, Nil Guler, Basak Unver Koluman, Mehmet Sonmez, Nergiz Erkut, Emin Kaya, Irfan Kuku, Mehmet Ali Erkurt, Gulsum Ozet, Funda Ceran, Fahri Sahin, Nur Soyer, Meliha Nalcaci, Mehmet Yilmaz, Sirac Bozkurt, Birkan Aver, Begum Ozdengulsun, Egemen Ozbilgili, Osman Ilhan","doi":"10.2217/ijh-2021-0008","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey.</p><p><strong>Materials & methods: </strong>Hospital records between 2005 and 2018 were retrospectively reviewed.</p><p><strong>Results: </strong>Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival.</p><p><strong>Conclusion: </strong>The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"11 3","pages":"IJH40"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/82/ijh-11-40.PMC9453544.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2021-0008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey.
Materials & methods: Hospital records between 2005 and 2018 were retrospectively reviewed.
Results: Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival.
Conclusion: The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.
期刊介绍：
International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
